Streetbeat News

Products Services

IFF

International Flavors & Fragrances, Inc.'s (NYSE:IFF) unit Danisco Animal Nutrition & Health has announced that its phytase enzyme, Axtra PHY GOLD, has been authorized for in-feed use in the EU. The enzyme does not interfere with digestion and animal performance and works faster than any other competitor's phytase to break down phytate present in grains. It is available globally in markets including the U.S., Latin America, Asia Pacific, and most recently in the EU. IFF shares are trading higher by 2.02% to $79.61.

Portfolio Pulse from Nabaparna Bhattacharya

July 07, 2023 | 4:51 pm

IGC

IGC Pharma, Inc. (AMEX:IGC) has secured a $12 million credit from the Hong Kong Branch of O-Bank Co., Ltd. The funding will support IGC's working capital needs primarily related to Alzheimer's research. The company's IGC-AD1 is currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer's. Bradbury Asset Management has collateralized cash assets in support of the line of credit.

Portfolio Pulse from Nabaparna Bhattacharya

July 07, 2023 | 4:43 pm

MBGYY

TSLA

Mercedes Benz Group ADR (OTC:MBGYY) will provide its customers with the option of using and access more than 12,000 Tesla, Inc. (NASDAQ:TSLA) Superchargers in North America starting in 2024. Mercedes-Benz will also establish its own High-Power Charging Network with more than 400 charging hubs, including more than 2,500 high-power chargers in North America by the end of the decade. The first Mercedes-Benz charging hubs in North America will be opened by the end of 2023.

Portfolio Pulse from Shivani Kumaresan

July 07, 2023 | 4:36 pm

ALZN

BIIB

LLY

SAVA

The FDA has fully approved Biogen Inc.’s Alzheimer’s treatment, Leqembi, making it the first Alzheimer’s antibody treatment to reach full approval. Following this, Medicare announced it will cover the treatment under certain conditions. Other companies with Alzheimer’s treatments in the pipeline include Eli Lilly & Co, Cassava Sciences Inc, and Alzamend Neuro Inc.

Portfolio Pulse from Aaron Bry

July 07, 2023 | 4:16 pm

META

Mark Zuckerberg, CEO of Meta Platforms Inc., announced that 70 million users have signed up on Threads as of Friday morning.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 3:54 pm

INM

InMed Pharmaceuticals Inc. (NASDAQ:INM) has published positive top-line data from its INM-755 Phase II study for the treatment of epidermolysis bullosa (EB), a rare genetic dermatological condition. The study supports further development of the cannabinol-based topical skin cream, INM-755. Following the data, InMed is exploring commercial partnerships for further development and distribution of the cream. The company is also open to early monetization opportunities through the sale or out-licensing of the program.

Portfolio Pulse from Javier Hasse

July 07, 2023 | 3:22 pm

INTC

Intel has resumed shipments of its fourth-gen Xeon Sapphire Rapids processors after a bug was discovered and mitigated. The bug affected a subset of the processors and led to a temporary halt in shipments. Intel has developed a firmware fix and is now distributing it to its partners. The company has not disclosed the specifics of the bug but confirmed that the mitigation will not impact performance.

Portfolio Pulse from Happy Mohamed

July 07, 2023 | 3:17 pm

CMPS

COMPASS Pathways (NASDAQ:CMPS) has projected a 2027 commercialization timeline for its psilocybin-assisted therapy, pending Phase 3 clinical trial success. The company is currently conducting a Phase 3 clinical program for its proprietary psilocybin formula, COMP360, for treatment-resistant depression. Additionally, COMPASS is undertaking concurrent Phase 2 clinical studies using COMP360 for PTSD and anorexia nervosa. H.C. Wainwright reiterated their 'Buy' rating on COMPASS Pathways, maintaining its $120 per share price target.

Portfolio Pulse from The Dales Report

July 07, 2023 | 3:13 pm

TGTX

TG Therapeutics, Inc. (NASDAQ:TGTX) shares are moving higher after the company reported first quarter product revenue from its drug Briumvi at $7.8 million and projected continued revenue growth. The stock is also receiving attention from retail investors and has a considerable short interest of 18.59%.

Portfolio Pulse from Erica Kollmann

July 07, 2023 | 3:06 pm

QTRX

Quanterix has launched LucentAD test, a tool to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease. This has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 2:43 pm